ESR1 and breast carcinoma: In the phase II randomized multi-arm trial NCT04075604, 136 ER+/HER2− breast cancer patients will be evaluated with reference to safety and efficacy endpoints following the administration of palbociclib and anastrozole with or without nivolumab, a human-programmed death receptor-1 (PD-1) blocking antibody [97].